Cluenex
Log inStart free
All stocks · Healthcare · Health Care Equipment

Revvity RVTY

Revvity scores weak on business quality (3.9 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$154.18Oct 10, 2026
Business qualityWeak
Next earningsNov 3, 2026, before the open
Insiders, 90 daysQuiet

Why it matters

  1. What Revvity does

    Revvity sells life science diagnostics and research tools to labs and biopharma companies, making money through consumables and instruments. The firm prepares for its upcoming earnings call on November 3, 2026, amid shifting life science research demand.

  2. What it does best

    Revvity maintains top decile free cash flow margins at 67.0%, besting peers like WAT at 8.6% and IQV at 12.9%. This cash conversion relies on sticky consumable streams tied to proprietary laboratory workflows that lock in clinical labs.

  3. The main risk

    A stagnant top line threatens earnings leverage, with revenue growth sitting in the bottom quartile at 3.7%. If lab spending cuts persist, the low 0.03% ROE leaves little cushion to absorb margin pressure.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityWeak

Operating margin stands at 12.3% with a gross margin of 55.0%, lagging sector medians. Profitability remains modest as scale benefits stay constrained.

MoatWeak

The moat relies on customer switching costs within life science tools, though a modest 3.7% ROE shows limited pricing power compared to peers like MTD.

GrowthSlow

Revenue grew at 3.7% recently, lagging historical periods and sitting in the bottom quartile of its sector. Top-line expansion remains sluggish as diagnostics demand normalizes.

Financial healthFair

Interest coverage sits at 3.8x against $2.3B of net debt, leaving debt servicing tight. Free cash flow reached $558.0M recently, showing stable generation despite soft growth.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

No open market buys or unplanned sales by executives or directors.

Our sealed record on RVTY

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is RVTY a good business?

Revvity scores weak on the Cluenex quality check (3.9 of 10), measured against its own industry. Profitability is weak, moat weak, growth slow and financial health fair.

Are insiders buying RVTY?

In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.

When does RVTY report earnings?

Nov 3, 2026, before the open.

For members

See RVTY today

  • Today's verdict on RVTY, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Revvity (RVTY)”, https://cluenex.com/stocks/rvty/, data as of Oct 10, 2026.